Targeting mGluR group III for the treatment of neurodegenerative diseases-Reference-Cited by-同舟云学术

Targeting mGluR group III for the treatment of neurodegenerative diseases

Published:2023-12 Issue: Volume:168 Page:115733
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Rabeh Nadia,Hajjar Baraa,Maraka Jude O.,Sammanasunathan Ashwin F.,Khan Mohammed,Alkhaaldi Saif M.I.,Mansour Samy,Almheiri Rashed T.,Hamdan Hamdan,Abd-Elrahman Khaled S.

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference213 articles.

1. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease;Williams;J. Neurochem.,2014

2. Molecular pathology of neurodegenerative diseases: principles and practice;Kovacs;J. Clin. Pathol.,2019

3. burden of neurodegenerative disease;Thorpe;Partn. Fight Chronic Dis. PFCD,2021

4. Activities of daily living and associated costs in the most widespread neurodegenerative diseases: a systematic review;Maresova;Clin. Inter. Aging,2020

5. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson’s disease;Montastruc;J. Neurol. Neurosurg. Psychiatry,1992

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the therapeutic capabilities of GPCR in the treatment of ischemic stroke: A translational literature;Medicine in Drug Discovery;2024-12

2. Interactions between metabotropic glutamate and CB1 receptors: implications for mood, cognition, and synaptic signaling based on data from mGluR and CB1R-targeting drugs;Pharmacological Reports;2024-06-28

3. Editorial: Emerging insights in glutamate receptor signaling in psychiatric, neurodevelopmental, and neurodegenerative diseases;Frontiers in Cell and Developmental Biology;2024-02-28